Saffron for Age-related Macular Degeneration
Small randomized trials suggest standardized saffron (20-50 mg/day) can modestly improve retinal function and visual acuity in early-to-intermediate dry age-related macular degeneration, but the evidence is preliminary and saffron is not a substitute for the established AREDS2 formula. Treat it, at most, as an experimental add-on rather than a proven therapy.
Why this grade7-layer evidence engine
The grade rests on a consistent but thin body of double-blind RCTs. Italian crossover work (PMID 24067115, n=100) and a 6-month extension (PMID 39507811, n=50) found that adding saffron 20 mg/day to background AREDS supplements raised focal-ERG amplitude (~0.3-0.4 log units) and best-corrected acuity by about 2 ETDRS letters. Two Iranian trials concur: 30 mg/day improved acuity by roughly 3 letters (PMID 20688744, n=60) and 50 mg/day improved acuity and contrast with a small drop in central macular thickness (PMID 39507811, n=80). A systematic review of 8 RCTs in 320 patients (PMID 30889784) reports the same direction of benefit.
Several limits keep this at preliminary, not strong, evidence. Almost all trials come from just two centers (Rome and Tehran), pooled enrollment is only ~300 people, follow-up is 3-12 months, and the acuity gains (2-3 letters) sit below the ~5-letter threshold patients typically notice. Crucially, no trial measured the endpoint that matters most in AMD: progression to late, sight-threatening disease.
Regulators and major clinics have not endorsed it. The FDA treats saffron only as a GRAS color/flavoring agent, and EFSA concluded 'a cause and effect relationship has not been established' for its health claims. Mayo Clinic and Harvard Health discuss only AREDS2 for AMD and do not mention saffron, and it is not in the AREDS2 formula or American Academy of Ophthalmology guidance. Saffron is generally safe at these doses but is contraindicated in pregnancy and may interact with anticoagulants and blood-pressure drugs.
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditable▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.655
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status